Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
Identifieur interne : 000B63 ( Main/Exploration ); précédent : 000B62; suivant : 000B64Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
Auteurs : Katrina L. Paumier [États-Unis] ; Andrew D. Siderowf ; Peggy Auinger ; David Oakes ; Lalitha Madhavan ; Alberto J. Espay ; Fredy J. Revilla ; Timothy J. CollierSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2012.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents, Tricyclic (therapeutic use), Cohort Studies, Depressive Disorder (drug therapy), Depressive Disorder (etiology), Depressive Disorder (mortality), Disability Evaluation, Dopamine Agents (therapeutic use), Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (mortality), Psychiatric Status Rating Scales, Retrospective Studies, Severity of Illness Index, Survival Analysis, Time Factors.
- MESH :
- chemical , therapeutic use : Antidepressive Agents, Tricyclic, Dopamine Agents.
- complications : Parkinson Disease.
- drug therapy : Depressive Disorder, Parkinson Disease.
- etiology : Depressive Disorder.
- mortality : Depressive Disorder, Parkinson Disease.
- Aged, Cohort Studies, Disability Evaluation, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Psychiatric Status Rating Scales, Retrospective Studies, Severity of Illness Index, Survival Analysis, Time Factors.
Abstract
This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.
DOI: 10.1002/mds.24978
PubMed: 22555881
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D81
- to stream PubMed, to step Curation: 000D81
- to stream PubMed, to step Checkpoint: 000B70
- to stream Ncbi, to step Merge: 003649
- to stream Ncbi, to step Curation: 003649
- to stream Ncbi, to step Checkpoint: 003649
- to stream Main, to step Merge: 000B64
- to stream Main, to step Curation: 000B63
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.</title><author><name sortKey="Paumier, Katrina L" sort="Paumier, Katrina L" uniqKey="Paumier K" first="Katrina L" last="Paumier">Katrina L. Paumier</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Cincinnati, Cincinnati, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D" last="Siderowf">Andrew D. Siderowf</name></author><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></author><author><name sortKey="Madhavan, Lalitha" sort="Madhavan, Lalitha" uniqKey="Madhavan L" first="Lalitha" last="Madhavan">Lalitha Madhavan</name></author><author><name sortKey="Espay, Alberto J" sort="Espay, Alberto J" uniqKey="Espay A" first="Alberto J" last="Espay">Alberto J. Espay</name></author><author><name sortKey="Revilla, Fredy J" sort="Revilla, Fredy J" uniqKey="Revilla F" first="Fredy J" last="Revilla">Fredy J. Revilla</name></author><author><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="doi">10.1002/mds.24978</idno><idno type="RBID">pubmed:22555881</idno><idno type="pmid">22555881</idno><idno type="wicri:Area/PubMed/Corpus">000D81</idno><idno type="wicri:Area/PubMed/Curation">000D81</idno><idno type="wicri:Area/PubMed/Checkpoint">000B70</idno><idno type="wicri:Area/Ncbi/Merge">003649</idno><idno type="wicri:Area/Ncbi/Curation">003649</idno><idno type="wicri:Area/Ncbi/Checkpoint">003649</idno><idno type="wicri:Area/Main/Merge">000B64</idno><idno type="wicri:Area/Main/Curation">000B63</idno><idno type="wicri:Area/Main/Exploration">000B63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.</title><author><name sortKey="Paumier, Katrina L" sort="Paumier, Katrina L" uniqKey="Paumier K" first="Katrina L" last="Paumier">Katrina L. Paumier</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Cincinnati, Cincinnati, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D" last="Siderowf">Andrew D. Siderowf</name></author><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></author><author><name sortKey="Madhavan, Lalitha" sort="Madhavan, Lalitha" uniqKey="Madhavan L" first="Lalitha" last="Madhavan">Lalitha Madhavan</name></author><author><name sortKey="Espay, Alberto J" sort="Espay, Alberto J" uniqKey="Espay A" first="Alberto J" last="Espay">Alberto J. Espay</name></author><author><name sortKey="Revilla, Fredy J" sort="Revilla, Fredy J" uniqKey="Revilla F" first="Fredy J" last="Revilla">Fredy J. Revilla</name></author><author><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antidepressive Agents, Tricyclic (therapeutic use)</term><term>Cohort Studies</term><term>Depressive Disorder (drug therapy)</term><term>Depressive Disorder (etiology)</term><term>Depressive Disorder (mortality)</term><term>Disability Evaluation</term><term>Dopamine Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (mortality)</term><term>Psychiatric Status Rating Scales</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Survival Analysis</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents, Tricyclic</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depressive Disorder</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Depressive Disorder</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Cohort Studies</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Kaplan-Meier Estimate</term><term>Male</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Survival Analysis</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with those not taking antidepressants. No significant differences were found in UPDRS scores for subjects taking antidepressants compared with those not taking antidepressants. Tricyclic antidepressants are associated with a delay in reaching the end point of need to start dopaminergic therapy. The lack of change in overall UPDRS scores suggests the delay was not attributable to symptomatic effects.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Ohio</li></region></list><tree><noCountry><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name><name sortKey="Collier, Timothy J" sort="Collier, Timothy J" uniqKey="Collier T" first="Timothy J" last="Collier">Timothy J. Collier</name><name sortKey="Espay, Alberto J" sort="Espay, Alberto J" uniqKey="Espay A" first="Alberto J" last="Espay">Alberto J. Espay</name><name sortKey="Madhavan, Lalitha" sort="Madhavan, Lalitha" uniqKey="Madhavan L" first="Lalitha" last="Madhavan">Lalitha Madhavan</name><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><name sortKey="Revilla, Fredy J" sort="Revilla, Fredy J" uniqKey="Revilla F" first="Fredy J" last="Revilla">Fredy J. Revilla</name><name sortKey="Siderowf, Andrew D" sort="Siderowf, Andrew D" uniqKey="Siderowf A" first="Andrew D" last="Siderowf">Andrew D. Siderowf</name></noCountry><country name="États-Unis"><region name="Ohio"><name sortKey="Paumier, Katrina L" sort="Paumier, Katrina L" uniqKey="Paumier K" first="Katrina L" last="Paumier">Katrina L. Paumier</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22555881
|texte= Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22555881" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |